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Abstract  4 
Background 5 
Traumatic brain injury (TBI) is a global health problem; worldwide, >60 million people 6 
experience a TBI each year and incidence is rising. TBI has been proposed as an independent 7 
risk factor for stroke.  8 
Aims 9 
To investigate the association between TBI and stroke risk. 10 
Summary of review 11 
We undertook a systematic review of MEDLINE, EMBASE, CINAHL, and The Cochrane 12 
Library from inception to 4th December 2020. We used random-effects meta-analysis to pool 13 
hazard ratios (HR) for studies which reported stroke risk post-TBI compared to controls. 14 
Searches identified 10,501 records; 58 full texts were assessed for eligibility and 18 met the 15 
inclusion criteria. The review included a large sample size of 2,606,379 participants from 16 
four countries. Six studies included a non-TBI control group, all found TBI patients had 17 
significantly increased risk of stroke compared to controls (pooled HR 1.86; 95% CI 1.46-18 
2.37). Findings suggest stroke risk may be highest in the first four months post-TBI, but 19 
remains significant up to five years post-TBI. TBI appears to be associated with increased 20 
stroke risk regardless of severity or subtype of TBI. There was some evidence to suggest an 21 
association between reduced stroke risk post-TBI and Vitamin K antagonists and statins, but 22 
increased stroke risk with certain classes of antidepressants. 23 
Conclusion 24 
TBI is an independent risk factor for stroke, regardless of TBI severity or type. Post-TBI 25 








Traumatic brain injury (TBI) is a global health problem; worldwide, more than 60 million 3 
people experience a TBI each year and incidence is rising.(1) Increased incidence of TBI has 4 
been attributed to increased falls in elderly populations, armed conflict, and sports related 5 
injury in high income countries, and increased road traffic accidents in low/middle income 6 
countries.(2, 3) 7 
Advances in critical care, imaging, and the reorganisation of trauma health systems have led 8 
to a reduction in TBI-related mortality.(4) However, increased survival rates results in more 9 
people living with the long-term effects of TBI. These long-term effects are wide-ranging, 10 
including physical, psychological, and cognitive disabilities, and can cause huge burden at 11 
individual, family, and societal levels.(5) Long-term impacts are not exclusive to severe TBI 12 
and are often experienced by patients with mild and moderate TBI.(6) 13 
TBI has also been associated with long-term risk of neurological diseases, including 14 
dementia, Parkinson's disease, Alzheimer’s disease, and epilepsy.(7-10) TBI has been proposed 15 
as an independent risk factor for stroke;(11) however, to our knowledge, no systematic reviews 16 
have explored stroke risk post-TBI. Stroke is a leading cause of death and disability 17 
worldwide, but stroke prevention medication and lifestyle change can reduce stroke risk.(12) 18 
Therefore, understanding the association between TBI and stroke is important to help inform 19 
healthcare for TBI patients. Characterising stroke risk post-TBI is particularly important 20 
given the changing epidemiology of TBI in high income countries among the elderly and the 21 
fact that older age is an independent risk factor for stroke. The aim of this review was to 22 
investigate the association between TBI and risk of stroke. 23 
 24 
Material and methods 25 
The review protocol was registered on PROSPERO prior to conducting literature searches 26 
(CRD42019121149).(13) The review methodology and reporting is in accordance with the 27 




Eligibility criteria 1 
Studies were eligible if they included adult participants (≥18 years) who had experienced a 2 
TBI (any severity) and reported frequency, incidence, or risk estimates of stroke and/or 3 
transient ischemic attack (TIA) at any time point post-TBI. Studies of mixed populations 4 
were eligible if it was possible to extract data of TBI participants.  5 
Eligible study designs were controlled, cohort, cross-sectional, and case control studies. Only 6 
peer-reviewed, full text publications or theses were included. To avoid language bias, non-7 
English papers were eligible.  8 
Information sources and search strategy 9 
Searches were performed with no publication date restrictions in the following bibliographic 10 
databases: MEDLINE, EMBASE, CINAHL, and The Cochrane Library. Grey literature was 11 
searched from the following sources: Grey Matters by CADTH, OpenGrey, and 12 
Epistemonikos. Reference lists of relevant studies were also reviewed. The initial search was 13 
performed from inception to 14th December 2018, followed by an updated search from 2018 14 
to 4th December 2020.  15 
A combination of text words and index terms related to the condition (TBI) and the outcome 16 
(stroke/TIA) were utilised (Supplementary Figure 1). 17 
Study selection, data extraction and critical appraisal 18 
Literature search results were exported to EndNote V.X8.0 (Thomson Reuters, New York) 19 
and duplicates removed. Titles and abstracts of search results were screened and full texts 20 
obtained for potentially eligible studies. A standardised, pre-determined eligibility criteria 21 
checklist was used to select eligible studies (Supplementary Table 1). Data were extracted on 22 
study design, population, outcomes, and findings using a standardised, piloted data extraction 23 
form (Supplementary Table 2). An adapted version of the REporting of studies Conducted 24 
using Observational Routinely-collected Data (RECORD) checklist was used to assess 25 
quality of included studies.(15) 26 
All study selection, data extraction, and quality assessment processes were conducted 27 
independently and in duplicate by three authors (GT, CM and OLA); discrepancies were 28 
resolved by an additional reviewer (AB).  29 
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Data synthesis and statistical analysis 1 
A random effects meta-analysis pooled hazard ratios (HRs) for studies which reported stroke 2 
risk post-TBI compared to non-TBI controls. The meta-analysis was performed using Review 3 
Manager Version 5.3. (Copenhagen: The Nordic Cochrane Centre, The Cochrane 4 
Collaboration, 2014). Studies without a non-TBI comparator were narratively summarised 5 
and tables were created to facilitate comparisons. A narrative subgroup analysis was 6 
conducted for studies which reported time to stroke onset post-TBI; severity or subtype of 7 
TBI; and stroke type (ischemic and haemorrhagic). 8 
Data availability 9 
Data are available on request. 10 
Results 11 
Searches identified 10,501 records, of which 58 full texts were assessed for eligibility, and 18 12 







Figure 1: PRISMA flow chart 2 
 3 
Study characteristics 4 
The 18 studies included 2,606,379 participants and were from the United States,(16-24) 5 
Taiwan,(25-31) Croatia,(32) and Denmark.(33) All were retrospective cohort studies and eight 6 
different data sources were used (Table 1), most commonly the Taiwan National Health 7 
Insurance Research Database(16-18, 20, 21, 31) and United States Medicare administrative claims 8 
data.(24-30) The eligibility criteria and definitions of TBI and stroke for included studies are 9 
summarised in Supplementary Table 3. 10 
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Six studies explored stroke risk post-TBI compared to non-TBI controls (Table 1).(19, 26-29, 31) 1 
Eight studies investigated the association of stroke risk post-TBI with specific exposures: 2 
antidepressants;(18, 20) statins;(21) oral anticoagulants;(16, 33) traumatic subarachnoid 3 
haemorrhage (tSAH);(23) acupuncture;(30) and insomnia.(25) Two studies reported frequency of 4 
stroke post-TBI without a comparator(22, 32) and two studies compared stroke incidence pre- 5 
























State Inpatient Databases; State 
Emergency Department 
Databases; Healthcare Cost and 
Utilization Project; and Agency 
for Healthcare Research and 
Quality 
Exposed: TBI patients 
(n=436,630) 
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Taiwan's National Health 
Insurance Research Database 
Exposed: mild TBI patients 
(n=24,905) 

















Taiwan's National Health 
Insurance Research Database 
Exposed: TBI patients 
(n=30,165) 





















Taiwan's National Health 
Insurance Research Database 
Exposed: patients with 
concussion (n=13,652) 


















Administrative claims data from 
USA Medicare beneficiaries 
Exposed: antidepressant use after 
TBI (n=15,733) 
79.7 (7.7) 9,852 (32) NR 
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Unexposed: no antidepressant 






Administrative claims data from 
USA Medicare beneficiaries 
Exposed: antidepressant used at 
least once after TBI (n=20,859) 
Unexposed: No antidepressant 
use after TBI (n=43,355) 






Administrative claims data from 
USA Medicare beneficiaries 
Exposed: statin use after TBI 
(n=50,173) 
Unexposed: no statins used after 
TBI (n=50,342) 






Administrative claims data from 
USA Medicare beneficiaries 
Exposed: warfarin use after TBI 
(n=5,811) 
Unexposed: no warfarin use after 
TBI (n=4,971) 






Danish national patient registry; 
Danish national prescription 
registry; Danish civil registration 
system 
Exposed: VKAs/NOACs after 
TBI in AF patients (n=979) 
Unexposed: no VKAs/NOACs 
after TBI in AF patients (n=421) 






Inpatient discharges: data from 
California Office of Statewide 
Health Planning and 
Exposed: TBI patients with 
tSAH (n=20,454) 










Development, NY Statewide 
Planning and Research 
Cooperative System, and Florida 
Agency for Health Care 
Administration 










Taiwan's National Health 
Insurance Research Database 
Exposed: TBI patients receiving 
acupuncture (n=7,409) 
























Taiwan's National Health 
Insurance Research Database: 
Longitudinal Health Insurance 
Database 2000 
Exposed: TBI patients with 
insomnia (n=1,174) 
Unexposed: non-TBI patients 
with insomnia (n=5,870) 
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Database of brain injury patients 
hospitalised in the general ICU 
at Karlovac General Hospital 











Administrative claims data from 
USA Medicare beneficiaries 





Administrative claims data from 
USA Medicare beneficiaries 
TBI patients (no comparator) (n= 
52,228) 
82.9 (7.9) 18,439 (35.3) NR 
ICU: Intensive Care Units; NOACs: Novel Oral Anticoagulants; NR: Not Reported; NY: New York; TBI: Traumatic Brain Injury; tSAH: 







Risk of stroke post-TBI 2 
Stroke risk compared to non-TBI controls 3 
Of the six studies that included a non-TBI control group, all found TBI patients had 4 
statistically significantly increased risk of stroke compared to controls. This association 5 
remained when confounding variables were adjusted for (Table 2). All studies matched on or 6 
adjusted for age and sex; the list of variables each study adjusted for are detailed in 7 
Supplementary Table 4. The pooled adjusted HR was 1.86 (95% Confidence Interval [CI] 8 
1.46-2.37) (n=544,762 TBI patients and 1,692,865 controls) (Figure 2).  9 
 10 
Table 2: Stroke risk compared to non-TBI controls and stroke risk pre/ post-TBI. 11 
Author 
























Ischemic TBI: NR (1.1) 
Controls: NR 
(0.9) 
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3 months:  
10.21 (8.71-
11.96) 
1 year:  
4.61 (4.16-
5.11) 












































Person years:  
TBI 48,371  
Control: 
2,793,892 


























































rate per 1,000 
Ischemic:  
Pre-TBI: 70.5  
Post-TBI: 84.4  
Haemorrhagi
c:  
Pre-TBI: 3.7  
Post-TBI: 23.9  




































CI: Confidence Interval; HR: Hazard Ratio; IQR: Interquartile Range; Max: Maximum; Min: 
Minimum; n: number; NR: Not Reported SD: Standard Deviation; TBI: Traumatic Brain Injury; 
%: percentage 
* Variables adjusted for are presented in Supplementary Table 4 
† Matched 1:3 on age, sex and year of index use of health care services 
§Matched 1:2 on age-, sex-, and age-adjusted Charlson Comorbidity Index score 
‡ Matched 1:4 on age and sex 




Figure 2: Random effects meta-analysis pooled estimates for stroke risk post-TBI 2 
compared to non-TBI controls (n=6 studies; 544,762 TBI patients and 1,692,865 3 
controls). 4 
 5 
Stroke risk pre- and post-TBI 6 
Two studies investigated stroke rates pre- and post-TBI.(17, 24) Both studies reported higher 7 
incidence rates of ischemic and haemorrhagic stroke post-TBI, compared to pre-TBI (Table 8 
2). .  9 
Stroke risk associated with specified exposures 10 
Three studies explored stroke risk associated with exposure to stroke prevention medication 11 
post-TBI (Table 3). For patients who had been prescribed Vitamin K antagonists (VKA) prior 12 
to TBI, continuation or resumption of these drugs after TBI was associated with reduced 13 
stroke risk post-TBI, compared to patients who had VKA prescriptions stopped post-TBI 14 
(Albrecht 2014: Relative Risk 0.83; 95% CI 0.72-0.96 and Staerk 2018: HR 0.58; 95% CI 15 
0.37-0.90). However, no association was found for continuation or resumption of novel oral 16 
anticoagulants (NOACs) (HR 0.85; 95% CI 0.43-1.68). Prescription of statins post-TBI was 17 
associated with reduced risk compared to TBI patients not prescribed statins post-TBI 18 
(Relative Risk 0.86; 95% CI 0.81-0.91).  19 
Two studies investigated antidepressant use in TBI patients aged ≥65 years, both used 20 
administrative claims data from United States Medicare beneficiaries between 2006 and 21 
2010. Kokhar (2017) reported, compared to no use of antidepressants post-TBI, new use (i.e. 22 
not prescribed before TBI) of serotonin norepinephrine reuptake inhibitors (SNRIs) and 23 
phenylpiperazine antidepressants (PPAs) were associated with increased risk of ischemic 24 
stroke (Relative Risk 1.36; 95% CI 1.06-1.73 and 1.31; 95% CI 1.02-1.68, respectively). 25 
They found new use of selective serotonin reuptake inhibitors (SSRIs) was associated with 26 
increased risk of haemorrhagic stroke (Relative Risk 1.26; 95% CI 1.06-1.50). However, no 27 
16 
 
associations were found for other antidepressant drug classes (Table 3). Albrecht (2018) 1 
found, compared to tricyclic antidepressants (TCAs), SSRI use was associated with increased 2 
risk of haemorrhagic stroke (Risk Ratio 2.47; 95% CI 1.30-4.70). However, other 3 
antidepressant drug class comparisons were not associated with stroke risk (Table 3). 4 
Exposures reported in the other three studies were insomnia,(25) acupuncture(30) and 5 
tSAH.(23) TBI patients with new onset insomnia (i.e. insomnia occurring post-TBI) had a 2-6 
fold increased stroke risk (HR 2.28; 95% CI 1.70-3.06) compared to insomnia patients 7 
without TBI.(25) Acupuncture treatment post-TBI was associated with decreased stroke risk, 8 
compared to TBI patients not receiving acupuncture (HR 0.59; 95% CI 0.50-0.69).(30) TBI 9 
patients with tSAH had decreased stroke risk compared to TBI patients without tSAH (HR 10 
0.77; 95% CI 0.63-0.94). 11 
 12 
Table 3: Stroke risk post-TBI associated with specific exposures: anticoagulants, statins, 13 
antidepressants, insomnia, tSAH and acupuncture.  14 
Author 
(year)  




























































































































































































































SSRI vs SNRI 
(ref SNRI): 1 
(0.88-1.12) 














































































































































NR Hazard Ratio 
0.59 (0.50-
0.69) 
CI: Confidence Interval; n: number; NOACs: Novel Oral Anticoagulants; NR: Not Reported; PPA: 
Phenylpiperazine Antidepressants SD: Standard Deviation; SNRI: Serotonin Norepinephrine Reuptake 
Inhibitors; SSRI: Selective Serotonin Reuptake Inhibitors; 
TBI: Traumatic Brain Injury; TCA: Tricyclic Antidepressants; TetCA: Tetracyclic Antidepressants; tSAH: 




*Note: numbers do not add up as a result of exclusion of events occurring during hospitalization for TBI 
and multiple simultaneous events. 
 1 
Time to stroke onset post-TBI 2 
Chen (2011) found stroke risk post-TBI was highest in the first three months of follow-up 3 
(HR 10.21; 95% CI 8.71-11.96), but remained significantly higher than non-TBI controls at 4 
five years follow-up (HR 2.32; 95% CI 2.17-2.47) (Table 2).  5 
Albrecht (2015) reported stroke incidence rates for TBI patients were highest two and four 6 
month’s post-discharge and there was a steep decrease between four to 12 months post-7 
discharge: incidence rates (per 1,000) for ischemic stroke at two months 183.5; four months 8 
112.3; six months 84.8; eight months 69.9; 10 months 70.3; 12 months 78.1, and 9 
haemorrhagic stroke at two months 98.5; four months 36.1; six months 17.3; eight months 10 
11.7; 10 months 12.8; 12 months 8.2.  11 
Similarly, Albrecht (2015) found stroke rates post-TBI were elevated in the first three months 12 
after discharge and levelled out between three to 24 months for ischemic stroke and 12 to 24 13 
months for haemorrhagic stroke (Supplementary Figure 2).  14 
In a subgroup analysis of people who survived longer than 12 months, Lee (2014) found TBI 15 
patients’ stroke risk, compared to non-TBI controls, remained statistically significant (HR 16 
1.38; 95% CI, 1.20-1.59). 17 
Four studies reported average time between TBI and onset of stroke: Ao (2017) 0.93 years 18 
(mean follow-up 2.71 years; Standard Deviation [SD] 0.69); Belavic (2015) 8.56 days (mean 19 
follow-up 29.13 days; SD 27.16); Lee (2014) 1.12 years (mean follow-up 1.94 years; SD 20 
1.18); Chen (2011) 1.49 years (maximum follow-up 5 years). 21 
Two studies reported frequency of stroke diagnosed during acute hospitalisation for TBI. 22 
Kowalski (2017) found 2.5% (159/6,488) of moderate to severe TBI patients had an ischemic 23 
stroke (median hospital duration 25 days, range 4-125 days). Belavic (2015) found 7.5% 24 
(23/306) of TBI patients had a stroke (mean time to stroke after TBI 7 ± 8 days and mean 25 
hospital duration 29 ± 27 days). 26 
Severity and subtype of TBI 27 
Two studies had populations of mild TBI patients, both reported increased stroke risk post-28 
TBI compared to non-TBI controls: Lee (2014) HR 1.46 (95% CI 1.33-1.62) and Liu (2017) 29 
20 
 
HR 1.65 (95% CI 1.47-1.85) (Table 2). In a secondary analysis stratified by trauma severity, 1 
Burke (2013) found ischemic stroke risk remained significantly higher than controls 2 
regardless of severity (tertile 1 [lowest severity]: HR 1.10; 95% CI 1.01-1.20, tertile 2: HR 3 
1.29; 95% CI 1.16-1.43, tertile 3 [highest severity]: HR 1.25; 95% CI 1.16-1.35). Similarly, 4 
Liao (2014) found increased risk of stroke post-TBI compared to controls for all types of 5 
TBI: mild TBI: HR 1.74 (95% CI 1.57-1.93); severe TBI: HR 2.04 (95% CI 1.89-2.20); skull 6 
fracture: HR 3.00 (95% CI 2.42-3.71). 7 
In a secondary analysis of trauma subtype, Burke (2013) found increased ischemic stroke risk 8 
compared to controls regardless of subtype: skull fracture HR 1.21 (95% CI 1.05-1.41); 9 
concussion HR 1.27 (95% CI 1.17-1.37); intracranial bleeding HR 1.21 (95% CI 1.12-1.31); 10 
other intracranial injury HR 1.38 (95% CI 1.07-1.76); and unspecified HR 1.33 (95% CI 11 
1.27-1.40). Chen (2011) found stroke risk, compared to controls, was more pronounced for 12 
TBI patients with skull fracture at 3 months (skull fracture: HR 19.98; 95% CI 14.73-27.22 vs 13 
without skull fracture: HR 9.75; 95% CI 8.31-11.45), one year (skull fracture: HR 8.39; 95% 14 
CI 7.47-10.89 vs without skull fracture: HR 4.44; 95% CI 4.00-4.93), and five years (skull 15 
fracture: HR 3.54; 95% CI 2.86-4.37 vs without skull fracture: HR 2.26; 95% CI 2.12-2.42). 16 
Stroke type 17 
Five studies reported stroke risk post-TBI by stroke type. Eric Nyam (2019) found higher risk 18 
of haemorrhagic stroke post-TBI, compared to controls, than ischemic stroke (HR 6.02; 95% 19 
CI 4.80-7.55 and HR 2.10; 95% CI 1.81-2.43, respectively) Chen (2011) reported higher risk 20 
of stroke post-TBI, compared to controls, for subarachnoid and intra-cerebral haemorrhagic 21 
stroke types than ischemic and unspecific strokes (subarachnoid haemorrhage: HR 4.89; 95% 22 
CI 3.81-7.19, intra-cerebral haemorrhage: HR 6.33; 95% CI 5.60-7.83, ischemic: HR 1.43; 23 
95% CI 1.31-1.56, unspecified:  2.21; 95% CI 1.99-2.44). Similarly, Albrecht (2015) and 24 
Glass (2019) found higher incidence rate ratios for haemorrhagic stroke post-TBI, compared 25 
to pre-TBI, than for ischemic stroke (Table 2). In contrast, Liu (2017) found higher 26 
cumulative incidence rates post-TBI for ischemic stroke compared to haemorrhagic stroke 27 
(8.9%; 95% CI 7.8-10.0 vs 2.7%; 95% CI 2.1-3.3, respectively) and similar adjusted HRs for 28 
stroke risk post-TBI, compared to controls, for both stroke subtypes (ischemic: HR 1.62; 95% 29 
CI 1.43-1.84 vs haemorrhagic: HR 1.73; 95% CI 1.36-2.20).  30 
21 
 
Study quality 1 
Critical appraisal of included studies (Supplementary Table 5) identified that the study design 2 
– including setting, recruitment, and follow-up dates – and eligibility criteria, were well 3 
described by all included studies. All studies, except one, clearly reported the clinical codes 4 
used to identify exposures and outcomes; however, only three studies referenced validation 5 
studies for these clinical codes and nine studies did not provide a complete list of clinical 6 
codes for confounders and other variables. Statistical methods were described well by most 7 
studies; however, none of the studies explained how missing data were addressed. 8 
Furthermore, none of the studies clearly described data cleaning methods and most studies 9 




This systematic review is the first to explore the association between TBI and stroke risk. The 14 
meta-analysis found TBI patients have 86% increased risk of stroke compared to non-TBI 15 
controls (HR 1.86; 95% CI 1.46-2.37). Stroke risk may be highest in the first four months 16 
post-TBI, but remains significant five years post-TBI. TBI is associated with increased stroke 17 
risk regardless of TBI severity or subtype. Furthermore, TBI is associated with increased risk 18 
of both ischemic and haemorrhagic stroke. VKAs, statins, and acupuncture use is associated 19 
with reduced stroke risk post-TBI; however, no association was found for NOAC use. Some 20 
classes of antidepressants – SNRIs, PPAs, and SSRIs – are associated with increased stroke 21 
risk post-TBI. 22 
Our findings suggest TBI is an independent risk factor for stroke regardless of TBI severity 23 
or subtype, even if it is mild and patients experience a good recovery. This is particularly 24 
noteworthy because 70-90% of TBIs are mild.(34) Stroke is the second leading cause of death 25 
and third leading cause of disability worldwide; however, urgent treatment can prevent stroke 26 
related death and long-term disability.(35, 36) Therefore, it may be beneficial to inform TBI 27 
patients of their potential increased stroke risk and educated them to recognise and respond 28 
urgently to stroke symptoms.  29 
Primary stroke prevention is important to reduce stroke incidence and subsequent stroke-30 
related death and disability; therefore, clinicians should review patients’ stroke risk post-TBI 31 
and consider administering stroke prevention medication and lifestyle advice. Our review 32 
22 
 
found some evidence to suggest an association between reduced stroke risk post-TBI and the 1 
stroke prevention drugs VKAs and statins. Furthermore, Khokhar (2018) found statin use 2 
post-TBI was also associated with decreased mortality, depression, Alzheimer’s disease, and 3 
related dementias. However, stroke prevention drugs are often stopped after an individual has 4 
experienced a TBI; Albrecht (2014) found 55% of patients who had been prescribed warfarin 5 
prior to TBI were not prescribed warfarin post-TBI(16) and Orlando (2013) found a statin 6 
discontinuation rate of 38% post-TBI for patients who took statins prior to TBI.(37) Other 7 
research has found older age and risk of falls are common barriers to clinicians’ prescribing 8 
stroke prevention drugs.(38) This is particularly relevant given the shift in TBI epidemiology 9 
in high income countries to falls in the elderly.(3) Future research is required to investigate 10 
the effectiveness of stroke prevention medication post-TBI and related adverse events to help 11 
inform clinicians’ prescribing and facilitate shared decision making. Future research should 12 
also explore clinical and demographic characteristics associated with increased stroke risk 13 
post-TBI to identify individuals most at risk of stroke post-TBI and help clinicians’ tailor 14 
preventative healthcare. 15 
Stroke risk may be highest in the first four months post-TBI; therefore, this time period is 16 
critical to educate patients about stroke risk and symptoms, and to administer stroke 17 
prevention medication and lifestyle advice. Importantly, stroke prevention medication, 18 
particularly VKAs and statins, should be re-started for patients who were prescribed these 19 
drugs prior to TBI. However, sequelae from TBI, such as physical and cognitive disability, 20 
may impair patients’ ability to engage with lifestyle change, adhere to medication, or 21 
recognise and respond to stroke symptoms. Therefore, rehabilitation post-TBI, including the 22 
role of carers and family members, should provide ongoing support for stroke prevention. 23 
Future research is required to further understand the temporal nature of stroke risk post-TBI. 24 
Our review found some evidence to suggest an association between some classes of anti-25 
depressants and increased stroke risk post-TBI. This potential association is important given 26 
that many people experience anxiety and depression post-TBI,(5) which are often treated 27 
with antidepressants. Khokhar (2017) found that a third of TBI patients were prescribed new 28 
use of antidepressants. A recent systematic review found antidepressant use is associated with 29 
increase stroke risk (Risk Ratio 1.41; 95% CI 1.13-1.69).(39) However, a study published 30 
since that review suggested antidepressants strongly inhibiting serotonin reuptake may be 31 
associated with a small decrease in the rate of ischemic stroke.(40) Further research is 32 
required into the safety of antidepressants specifically for TBI patients. 33 
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The mechanism for increased stroke risk post-TBI is unknown and is an area for future 1 
research; however, a number of hypotheses have been suggested. Damage to the 2 
cerebrovascular system caused by TBI could cause stroke through clot formation, damaged 3 
arteries, dissection, or increased intracranial pressure and blood pressure.(26) This could be 4 
identified by routine screening for damage to the cerebral vasculature post-TBI and is an area 5 
for future research. Alternatively, increased stroke risk may be due to lifestyle changes post-6 
TBI, such as a more sedentary lifestyle due to physical, cognitive, or psychological long-term 7 
effects.(28) Finally, TBI patients may be more likely to be prescribed antipsychotic and 8 
antidepressant drugs for TBI-related psychiatric and psychological disorders. These drugs 9 
have been associated with increased stroke risk.(18, 21, 41) 10 
The review is methodologically robust; all screening, data extraction and quality assessment 11 
processes were completed in duplicate. Non-English language papers were eligible to reduce 12 
language bias, although none were eligible. However, only peer-reviewed journal articles or 13 
theses were eligible which may introduce publication bias. The review included a large 14 
sample size of 2,606,379 participants from four countries. However, only six out of the 18 15 
studies compared stroke risk to non-TBI controls and studies were heterogeneous in terms of 16 
study population and duration of follow-up. Furthermore, all included studies were 17 
retrospective cohort studies which used data collected for routine clinical practice. Potential 18 
sources of bias from use of routine data for observational research include misclassification 19 
bias, missing data, unmeasured confounding, and changes in coding practices or database 20 
eligibility criteria.(15) In addition, information on stroke type, TBI classification and TBI 21 
severity were missing from the majority of studies. The association of stroke risk with 22 
treatment (in both directions) may be confounded by indication bias. Therefore, the review 23 
findings should be interpreted cautiously. The included studies were generally good quality in 24 
terms of study design and reporting; however, none of the studies clearly reported data 25 
cleaning processes and there was a lack of reporting of population selection based on data 26 
quality, availability, and linkage. This information is important because choice of data 27 
cleaning methods and population selection can affect study findings and reproducibility. 28 
Finally, most of the studies included administrative databases, which implies that the TBI 29 
definition might be inconsistent. However, in practice, these databases provide large sample 30 
sizes, thereby increasing reliability and validity. 31 
Our findings suggest TBI is an independent risk factor for stroke, regardless of TBI severity 32 
or subtype. There is some evidence to suggest stroke risk may be highest in the first four 33 
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months post-TBI; however, remains increased up to five years post-TBI. VKAs and statins 1 
may reduce stroke risk post-TBI; however, are frequently stopped post-TBI. Post-TBI review 2 
and management of risk factors for stroke may be warranted to mitigate the excess risk of 3 
stroke associated with TBI. Future research should investigate which subgroups are most at 4 
risk of stroke post-TBI; the temporal nature of stroke risk post-TBI; the effectiveness of 5 
stroke prevention medication post-TBI; the safety of antidepressants post-TBI and the 6 
mechanism of stroke risk post-TBI. 7 
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Supplementary material 7 
Supplementary Figure 1: Search strategy for MEDLINE 8 
1     traumatic brain injur$.mp. 9 
2     brain injuries/ or brain hemorrhage, traumatic/ or exp brain injuries, diffuse/ or exp brain 10 
injuries, traumatic/  11 
3     diffuse axonal injur$.ti,ab.  12 
4     (brain adj1 (injur$ or damage$ or concussion$ or contusion$ or trauma$ or coup-13 
contrecoup)).ti,ab.  14 
5     head injuries, penetrating/ or head injuries, closed/ or Wounds, Penetrating/ 15 
6     ((head or skull) adj1 (injur$ or trauma$ or fracture$)).ti,ab.  16 
7     Skull Fractures/  17 
8     exp Intracranial Hemorrhage, Traumatic/ or exp Cerebral Hemorrhage, traumatic/  18 
9     Craniocerebral Trauma/  19 
10     ((craniocerebral or intracranial or intracerebral or intraventricular or subarachnoid) adj1 20 
(trauma$ or injur$ or h?emorrhage$ or h?ematoma$)).ti.  21 
11     1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10  22 
12     exp Stroke/  23 
13     "National Institute of Neurological Disorders and Stroke (U.S.)"/  24 
14     exp "Intracranial Embolism and Thrombosis"/ or intracranial embolism.ti,ab. or 25 
intracranial thrombosis.ti,ab.  26 
15     Cerebral Infarction/  27 
16     Arteriovenous Malformations/ or arteriovenous malformation$.ti,ab.  28 
17     Aneurysm/ or aneurysm.ti,ab.  29 
18     Ischemic Attack, Transient/ or "transient isch?emic attack".ti,ab.  30 
19     12 or 13 or 14 or 15 or 16 or 17 or 18  31 
20     11 and 19  32 
21     limit 20 to humans  33 
22     21 not (editorial or letter or case report$ or comment$ or review or meta-analys?s or 34 
practice-guideline).pt.  35 
23     cohort studies/ or longitudinal studies/ or follow-up studies/ or prospective studies/ or 36 
retrospective studies/ or (cohort or longitudinal or prospective or retrospective).ti,ab. 37 
26 
 
24     Case-Control Studies/ or Control Groups/ or Matched-Pair Analysis/ or (case$ adj3 1 
(comparison$ or control$)).ti,ab.  2 
25     (observational stud$ or comparative stud$ or controlled stud$).ti,ab.  3 
26     Cross-Sectional Studies/ or Prevalence/ or (cross-sectional or prevalence or 4 
transversal).ti,ab.  5 
27     clinical trials as topic/ or ((randomi?ed or non-randomi?ed) adj3 trial$).ti,ab.  6 
28     23 or 24 or 25 or 26 or 27  7 
29     22 and 28  8 
 9 
 10 
Supplementary Figure 2: Monthly rates of adverse events/100 Medicare beneficiaries 11 
during the 2 years following hospitalization for traumatic brain injury, regardless of 12 
antidepressant use, n = 30,886. Figure copied from Albrecht JS, Rao V, Perfetto EM, Daniel 13 
Mullins C. Safety of Antidepressant Classes Used Following Traumatic Brain Injury Among 14 











Supplementary Table 1: Template eligibility criteria checklist 
Endnote ID   
Author (year)  
Population (Y/N)  
Comparator (Y/N)  
Outcomes (Y/N)  
Study type (Y/N)  
Report characteristics (Y/N)  
Include? (Y/N)  


















Paper ID    
Author    
Year of publication    
Country of origin    









   
Aim    
Study design    
Location    
Setting    
Eligibility criteria Inclusion   
  Exclusion  
Recruitment procedures    
Recruitment timeframe    
Follow-up timeframe    
Sample size TBI patients  













Study arms    
Diagnostic criteria for TBI     
Mechanism of injury    
Time since injury    
Severity of TBI    
TBI severity markers Loss of consciousness   
  Post traumatic amnesia   
GOS  
  Other  
Age (mean + SD/ Median + 
IQR) 
  






   
Ethnicity    
Deprivation    
Comorbidities    
Stroke risk factors BMI   
BP  
  Cholesterol   
Smoking status  
Other relevant 
characteristics 












Summary of analyses Primary   
Secondary  
Diagnostic criteria for stroke    
Measurement of stroke/TIA 
e.g. self-report 
  
Stroke or TIA in FU (n, %) TBI patients   
Control/ comparator  
Risk estimates (RR/ OR/ HR) Unadjusted   
Adjusted  
  Variables adjusted for  
Other relevant analyses    








Supplementary Table 3: Summary of participants, eligibility criteria, TBI severity, age, sex and length of follow-up for included studies. 
Author 
(year) 
Participants Eligibility criteria Length of 
follow up 




TBI: 10,782 Age ≥65 years; survival to hospital 
discharge; receipt of warfarin sodium 
in the month preceding TBI; no TBI 
episode in the 6 months prior to the 
index TBI event. 
12 months ICD-9-CM codes: 800.xx, 




ICD-9 CM 430.xx-432.xx 
ischemic stroke: ICD-9 
CM 433.xx, 434.xx, 




TBI: 16,936 Aged ≥65 years; minimum of 6 
months of observation time before 
the TBI hospitalization; excluded 
patients who died in the hospital or 
whose first hemorrhagic or ischemic 
stroke occurred within two weeks of 
admission for/discharge from TBI 
Min 6 months, 
max 48 months 
ICD-9 codes 800.xx, 
801.xx, 803.xx, 804.xx, 
850.xx- 854.1x, 950.1-
950.3, 959.01 in any 
position on an inpatient 
claim between 1st Jun 




Ischemic stroke: ICD-9 
codes 433.xx-435.xx, 
437.0x, and 437.1x 
(in any position on a 
claim with an admission 
date at least 14 days after 
the discharge date for the 
first TBI hospitalization 






TBI: 30,886 Aged ≥65 years; first TBI; survival 
to hospital discharge; 24 months 
continuous coverage post-TBI 
hospitalization; exclusively using 
one class of antidepressants or 
another during the post-TBI period; 
excluded patients who switched from 
one antidepressant class to another 











ICD-9-CM codes 800.xx, 
801.xx, 803.xx, 804.xx, 
F16850.xx–854.1x, 950.1–
950.3, or 959.01 in any 






CM codes 433.xx, 














TBI patients with new-onset 
insomnia; aged  ≥18 years; 1:5 age- 
and gender-matched cohort with 
insomnia; excluded pre-existing 
insomnia and stroke history before 





Skull bone fracture TBI 
(ICD-9-CM: 801-804) and 
non-skull bone fracture 
TBI (ICD-9-CM: 850-854) 
New-onset stroke of 






transient ischemic attack 
(ICD-9-CM: 435), and 
acute but ill-defined 
33 
 






TBI: 306 Patients with brain injury who were 
hospitalised in the general ICU at 













TBI: Aged ≥18 years who survived 
either an inpatient admission or an 
ED visit for TBI or trauma. 
Controls: patients who had a 
fracture, excluding fractures of the 
head and neck. 
Excluded individuals with stroke 
before TBI or trauma, and all 
patients with carotid or vertebral 







or 959.01 in any discharge 
diagnosis field 
Any hospitalization with 
a discharge diagnosis of 
ischemic stroke: ICD-9-
CM 433.x1, 434.x1, and 
436 from 2005 to 2009 
ED visits that did not 
result in admission for 
ischemic stroke were not 
included in the primary 
outcome because of 
concerns about the 









on age, sex 
and year of 
index use of 
health care 
services) 
Adults ≥18 years; excluded patients 
with diagnosis of acute stroke 
simultaneously during admission; 
diagnosed with stroke before their 
index use of health care services 
3 months, 1 
year, 5 years 
ICD-9-CM codes 801–804 
or 850–854 
















Adults ≥18 years; excluded people 
who had circulatory system disease 
before TBI occurrence and who had 
missing 
information about gender or age. 
Median: 5 
years, range 
0.0027 to 5 
years 
ICD-9-CM codes: 800, 
801, 803, 804, 850-853, 







TBI: 52,228 Survival to hospital discharge with 
continuous enrollment in Medicare 
parts A, B, and D with no part C 
enrolment for 6 months before the 
date of hospital admission for TBI 
and 12 months after TBI 
12 months ICD-9-CM codes: 800.xx, 
801.xx, 803.xx, 804.xx, 
850.xx- 854.1x, 950.1-
950.3, 959.01 on an 
inpatient claim 
ICD-9-CM 
codes in any position on 
an inpatient claim.  
Hemorrhagic: 430.xx-
432.xx 
Ischemic 433.xx, 434.xx, 




TBI: 64,214 Aged ≥65 years; excluded 
individuals with any antidepressant 
use six months prior to their TBI and 








ICD-9-CM codes 800.xx, 
801.xx, 803.xx, 804.xx, 
850.xx–854.1x, 950.1–
950.3, and 959.01 in any 
position. Any TBI 
occurring within 14 days 
of the previous TBI was 
collapsed as a single TBI 
event 
Inpatient claims using 
ICD-9-CM codes 430.xx–
432.xx (hemorrhagic 
stroke) and 433.xx, 
434.xx, 435.xx, 437.0x, 
437.1x (ischemic stroke) 




TBI: 100,515 Aged ≥65 years; survived a TBI 
hospitalization; 6 months of 
observation time prior to TBI. 
Up to 54 
months 
Identified by inpatient 
claims using ICD-9-CM 
codes 800.xx, 801.xx, 
803.xx, 804.xx, 850.xx-
Inpatient claims using 
ICD-9 codes 430.xx-
432.xx (hemorrhagic 
stroke) and 433.xx, 
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854.1x, 950.1-950.3, and 
959.01. 
434.xx, 435.xx, 437.0x, 




TBI: 6,488 Patients with acute, moderate to 
severe TBI; aged ≥16 years at injury, 
presentation to a Model System 
designated acute hospital within 72 
hours of injury and at least one of the 
following: post-traumatic amnesia 
(PTA) >24 hours, loss of 
consciousness >30 minutes, a 
Glasgow Coma Scale score <13 on 
initial presentation to a health care 
facility, or trauma-related 





ICD-9 433.01; 433.11; 
433.21; 433.31; 433.81; 
434.01; 434.11; 434.91  
TBI is defined for the 
TBIMS NDB as brain 
tissue damage caused by 
an external mechanical 
force. 
ICD-9 CM 433.01 to 







Aged ≥18 years; mild TBI; excluded 
patients with any type of stroke 
diagnosed before January 1, 2007,  
patients diagnosed with hemorrhagic 






Person years:  
Mild TBI was defined by 
the ICD-9-CM code for 
head concussion (850.0, 
850.1, 850.5, or 850.9), 
intracranial injury of other 
and unspecified nature 
Ischemic: ICD-9-CM 
codes 433–437 
(To maximize case 
ascertainment, only 
included patients 
hospitalized for stroke) 
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and patients who had ever been 
hospitalized with TBI. 
TBI 48,371  
Control: 
2,793,892 








on age and 
sex) 
Newly diagnosed TBI or patients 
without TBI; aged ≥20 years; 
excluded patients with TBI and 
stroke before the index date and 
patients who died within 30 days 
after TBI. 
Max 4 years ICD-9-CM codes 800, 















Concussion: first episode of 
concussion; aged >40 years; no 
intracranial injury identified at least 
one year before, no prior stroke 
events or an inadequate follow-up 
period (<6 months) 
Control: no concussion; no prior 
stroke events or an inadequate 
follow-up period (<6 months) 
Person years: 
154,657 
Concussion: ICD-9 850.X 
at either an out-patient 
clinic or emergency 
department. 
(The first episode of 
concussion was defined 
by: (1) No other 
intracranial injury (ICD-9 
801.x–805.x, 851.x–854.x, 
907.0) diagnosed one 
week before and after the 
diagnosis of concussion; 
Stroke-related 
hospitalization 
determined by the 
hospitalization records 
with a discharge 
diagnostic code of stroke 
(ICD-9 code, 430.x–
435.x) or death by the 




(2) First concussion event 
happened between 1 
January 1998 and 31 
December 2005 without 
any intracranial injury 










Aged ≥18 years; discharged alive 
after a first-recorded hospitalization 
with TBI; excluded patients with 
history of ischemic stroke  
Mean years 
(SD) 4.3 (1.8) 
ICD-9-CM codes 800.0-
801.9, 803.0-804.9, 850.0-
854.1, or 959.01 in any 
hospital discharge 
diagnosis field  
Patients with multiple 
visits for TBI were entered 
into the cohort at their 
index visit. 
Ischemic stroke defined 
as ICD-9-CM codes 
433.x1, 434.x1, or 436 in 
the absence of a primary 
discharge code for 
rehabilitation (V57) or 
any diagnosis code for 
intracerebral hemorrhage 







Aged ≥20 years with newly 
diagnosed TBI; only new-onset TBI 
cases were included; excluded 
people with previous medical records 













index date; TBI patients with only 
one course of acupuncture treatment. 
The non-acupuncture group included 
patients with TBI who did not have 
acupuncture treatment before the 










AF patients treated with VKA or 
NOAC the day before a traumatic 
injury hospital admission; aged 30-
100 years; excluded patients with 
valvular disease, total hip or knee 
arthroplastic within five weeks, 
pulmonary embolism or deep vein 
thrombosis within six months or no 
OAC treatment before traumatic 
injury. 
3 years ICD10: S020, S021, S027, 
S028, S040, S06, S07, 
S097, S099. 
Defined from diagnosis 
of ischemic stroke, 
transient ischemic attack, 
or systemic 
thromboembolism. 






Supplementary Table 4: Variables adjusted for in regression analyses for the included 
studies (n=16 studies) 
Author (year) Variables 
Albrecht (2014) Age, sex, race, lagged warfarin use, 30-day period after TBI 
(continuous), other anticoagulant use in the 30-day period after TBI, 
length of hospital stay (categorical), and discharge to skilled nursing 
facility. hemorrhagic models were adjusted for atrial fibrillation, liver 
disease, chronic kidney disease, ethanol abuse, malignant neoplasm, 
hypertension, anemia, coagulation defect, neurological disease, pre-TBI 
hemorrhagic event, and thrombotic event during period. Thrombotic 
models were adjusted for stroke or transient ischemic attack, 
hypertension, diabetes mellitus, heart failure, pre-TBI thrombotic event, 
and hemorrhagic event during period.  
Albrecht (2015) Not reported 
Albrecht (2018) Ischemic: Age, sex, race, atrial fibrillation, heart failure, diabetes, liver 
disease, neurologic disease, hip fracture, hypertension, ischemic heart 
disease, stroke, pre-TBI use of each of the compared classes (2 indicator 
variables) 
Hemorrhagic: Age, sex, race, atrial fibrillation, heart failure, chronic 
obstructive pulmonary disease, hip fracture, osteoarthritis, stroke, pre-
TBI use of each of the compared classes (2 indicator variables) 
Ao (2017) Age, gender, socioeconomic status, and comorbidities (hypertension, 
diabetes, Hyperlipidemia, coronary artery disease, renal)  
Belavic (2015) Not applicable 
Burke (2013) Demographics, payer, vascular risk factors (hypertension, 
hyperlipidemia, diabetes, atrial fibrillation), all Charlson comorbidities, 
trauma severity, whether a patient had multiple visits for trauma/TBI, 
and trauma mechanism, while accounting for clustering at the hospital 
level. 
Chen (2011) Stratified on sex, age, and year of index healthcare use with cases 
censored if individuals died from non-stroke causes during the follow-up 
period. Adjustments were made for patient’s monthly income, 
geographic region (Northern, Central, Eastern, and Southern Taiwan), 
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and select comorbidities (hypertension, diabetes coronary heart disease, 
heart failure, atrial fibrillation and hyperlipidemia) 
Eric Nyam 
(2019) 
Age, sex, group of age-adjusted Charlson Comorbidity Index score, 
hypertensive, chronic obstructive pulmonary disease, diabetes mellitus, 
renal disease and liver disease. 
Glass (2019) Not applicable 
Khokhar (2017) All adjusted generalized estimating equation models included age, sex, 
race, discharge to skilled nursing facility, length of hospital stay, 
warfarin use in period, depression (history of and recently diagnosed), 
atrial fibrillation, Alzheimer’s disease and related dementias, and 
hypertension. The ischemic stroke model also included hyperlipidemia, 
diabetes, ischemic heart disease, congestive heart failure, and prior 
ischemic stroke; while the hemorrhagic stroke model also included liver 
disease, chronic kidney disease, neurological disease, alcohol abuse, 
anemia, coagulation defect, valvular heart disease and prior hemorrhagic 
stroke. The composite stroke model included all variables from both 
ischemic and hemorrhagic stroke models.  
Khokhar (2018) Age, race, sex, county-level income, low-income subsidy status, region, 
congestive heart failure, acute myocardial infarction, ischemic heart 
disease, valvular heart disease, hyperlipidemia, hypertension, diabetes; 
Alzheimer’s disease and related dementias; count of Chronic Condition 
Data Warehouse chronic conditions excluding cardiovascular disease 
and Alzheimer’s disease and related dementias, and diabetes, length of 
hospital stay, discharge status, independent survival risk ratio,  
healthcare provider characteristics per 100 000 population (physicians, 
hospitals, hospitals with trauma services, hospitals with neurological 
services, beds); pre–TBI statin use, medication use in month 
(anticoagulant use, antiplatelet use, β-blocker) and history of any stroke, 






Lee (2014) Age, sex, urbanization level, socioeconomic status, diabetes, 
hypertension, coronary artery disease, hyperlipidemia, history of alcohol 
intoxication, malignancies, heart failure, atrial fibrillation, smoking, 
obesity, epilepsy, peripheral artery disease and Charlson Cormobidity 
Index score 
Liao (2014) Age, sex, urbanization, low income, hypertension, diabetes, mental 
disorders, chronic obstructive pulmonary disease, hyperlipidemia, 
parkinsonism, migraine, epilepsy, renal dialysis, smoking cessation and 
alcohol related illnesses 
Liu (2017) Age at index date, sex, hypertension, diabetes, arrhythmia, coronary 
artery disease, medication exposure 
Morris (2016) Not reported 
Shih (2014) Age, sex, low income, traditional Chinese medicine (TCM) physician 
density, type of TBI, diabetes mellitus, hypertension, hyperlipidemia, 
mental disorder, ischemic heart disease, migraine, epilepsy, 
anticoagulants, antiplatelet agents, and lipid lowering agents 
Staerk (2018) Calendar year, age (continuous), sex, and type of traumatic injury. All-
cause mortality models were further adjusted for CHA2DS2-VASc and 
HAS-BLED factors, stroke models for CHA2DS2-VASc factors, major 
bleeding models for HAS-BLED factors, and recurrent traumatic injury 
models for CHA2DS2-VASc and HAS-BLED factors, osteoporosis, 
dementia, and benzodiazepine usage. 
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Supplementary Table 5: Critical appraisal of included studies using an amended version of the REporting of studies Conducted using 

































































































































































































1 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
2 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
3 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
4 N/A N/A N/A ● N/A N/A ● ● N/A N/A N/A N/A N/A ● ● ● ● N/A 
5 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
6 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
7 N/A N/A N/A N/A N/A ● N/A N/A N/A N/A N/A N/A N/A N/A N/A ● N/A ● 
8 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
9 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
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10 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
11 N/A N/A N/A ● N/A ● ● ● N/A ● N/A N/A ● ● ● ● ● ● 
12 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
13 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
14 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
15 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
16 ● ● ● N/A N/A ● ● ● ● N/A N/A N/A ● ● N/A ● N/A ● 
17 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
18 ● N/A ● N/A N/A ● N/A N/A N/A ● ● ● N/A N/A ● ● N/A ● 
19 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
20 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
21 N/A N/A N/A N/A N/A ● N/A N/A N/A N/A N/A N/A N/A N/A N/A ● N/A ● 
22 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
23 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
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24 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
25 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
26 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
27 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
28 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
29 ● ● ● ● ● ● ● ● ● ● ● ● ● ● N/A ● ● ● 
30 ● ● ● ● N/A ● ● ● ● ● ● ● ● ● ● ● N/A ● 
31 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
32 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
33 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
34 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
35 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
36 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 






1 Study design Present key elements of study design early in the paper 
2 Setting Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and 
data collection 
3 Participants Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of 
follow-up 
4  For matched studies, give matching criteria and number of exposed and unexposed 
5  The methods of study population selection (such as codes or algorithms used to identify subjects) should be 
listed in detail. If this is not possible, an explanation should be provided. 
6  Any validation studies of the codes or algorithms used to select the population should be referenced. If 
validation was conducted for this study and not published elsewhere, detailed methods and results should be 
provided. 
7  If the study involved linkage of databases, consider use of a flow diagram or other graphical display to 
demonstrate the data linkage process, including the number of individuals with linked data at each stage. 
8 Variables Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic 
criteria, if applicable. 
9  A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect 
modifiers should be provided. If these cannot be reported, an explanation should be provided. 
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10 Data sources/ 
measurement 
For each variable of interest, give sources of data and details of methods of assessment (measurement). 
11  Describe comparability of assessment methods if there is more than one group 
12 Bias Describe any efforts to address potential sources of bias 
13 Study size Explain how the study size was arrived at 
14 Quantitative variables Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were 
chosen, and why 
15 Statistical methods Describe all statistical methods, including those used to control for confounding 
16  Describe any methods used to examine subgroups and interactions 
17  Explain how missing data were addressed 
18  Describe any sensitivity analyses 
19 Data access and 
cleaning methods 
Authors should describe the extent to which the investigators had access to the database population used to 
create the study population. 
 20  Authors should provide information on the data cleaning methods used in the study. 
21 Linkage State whether the study included person-level, institutional-level, or other data linkage across two or more 
databases. The methods of linkage and methods of linkage quality evaluation should be provided. 
RESULTS   
22 Participants Report the numbers of individuals at each stage of the study (e.g., numbers potentially eligible, examined for 
eligibility, confirmed eligible, included in the study, completing follow-up, and analysed) 
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23  Describe in detail the selection of the persons included in the study (i.e., study population selection) 
including filtering based on data quality, data availability and linkage. The selection of included persons can be 
described in the text and/or by means of the study flow diagram. 
24 Descriptive data Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and 
potential confounders 
25  Indicate the number of participants with missing data for each variable of interest 
26  Summarise follow-up time (e.g., average and total amount) 
27 Outcome data Report numbers of outcome events or summary measures over time 
28 Main results Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% 
confidence interval). Make clear which confounders were adjusted for and why they were included 
29  Report category boundaries when continuous variables were categorized 
30 Other analyses Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses 
DISCUSSION   
31 Key results Summarise key results with reference to study objectives 
32 Limitations Discuss the implications of using data that were not created or collected to answer the specific research 
question(s). Include discussion of misclassification bias, unmeasured confounding, missing data, and changing 
eligibility over time, as they pertain to the study being reported. 
33 Interpretation Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, 
results from similar studies, and other relevant evidence 
34 Generalisability Discuss the generalisability (external validity) of the study results 
OTHER INFORMATION   
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35 Funding Give the source of funding and the role of the funders for the present study and, if applicable, for the original 
study on which the present article is based 
36 Accessibility of 
protocol, raw data, 
and programming 
code 
Authors should provide information on how to access any supplemental information such as the study protocol, 
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